A Study of Amivantamab in Combination With Lazertinib, or Amivantamab in Combination With Platinum-Based Chemotherapy, for Common Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)
NCT06667076
This study is recruiting at 13 US sites in 9 states, according to its ClinicalTrials.gov record last updated .
Summary
The primary purpose of the study is to assess how well amivantamab in combination with lazertinib or in combination with chemotherapy works (antitumor activity) in participants with epidermal growth factor receptor mutated (EGFRm) non-small cell lung cancer (NSCLC; that is one of the major types of lung cancer).
Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov
Conditions studied
- Carcinoma, Non-Small-Cell Lung
Eligibility basics and study details
- Study type
- Interventional
- Phase
- Phase 2
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Sponsor
- Janssen Research & Development, LLC
- Last updated on ClinicalTrials.gov
- November 3, 2026
These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.
US recruiting sites
California · 4
- City of Hope Antelope Valley · Lancaster, CA
- City of Hope Long Beach Elm · Long Beach, CA
- City of Hope South Pasadena · South Pasadena, CA
- City of Hope Upland · Upland, CA
Florida · 2
- Memorial Regional Hospital · Hollywood, FL
- Memorial Cancer Institute · Pembroke Pines, FL
Georgia · 1
- Grady Health System Correll Pavilion · Atlanta, GA
Illinois · 1
- City of Hope Chicago · Zion, IL
Maryland · 1
- University of Maryland · Baltimore, MD
Missouri · 1
- Truman Medical Ctr West · Kansas City, MO
New Jersey · 1
- Overlook Medical Center · Summit, NJ
Tennessee · 1
- SCRI Oncology Partners · Nashville, TN
Texas · 1
- Parkland Health and Hospital System · Dallas, TX
Source: ClinicalTrials.gov, data processed . Recruiting US sites filtered by distance and site status; summaries shortened.